BioWorld: “In The Clinic” Spotlights MYOS Fortetropin™ Clinical Trial

Originally published in BioWorld™ Today, Volume 25, No. 138

Myos Corp., of Cedar Knolls, N.J., reported positive top-line results of its trial designed to study the effects of Fortetropin (MYO-T12) in conjunction with modest resistance training in male subjects. The trial was designed to analyze important body composition measurements and strength performance at two dose levels of Fortetropin over a 12-week period. The randomized, double-blind, placebo controlled study clinically demonstrated that Fortetropin resulted in statistically significant increases in both muscle size and lean body mass in average males. The study evaluated 45 male subjects adhering to a supervised nutritional intake program and a monitored modest resistance training regimen over a period of 12 weeks. The various endpoints included skeletal muscle hypertrophy, lean body mass, fat mass and measurements of strength and power. Subjects taking the product showed significantly improved lean body mass and increased muscle size compared to placebo.

Click here to read the official MYOS Corporation press announcement from July 22, 2014.